ASIA-CHINA ·...

ASIA-CHINA

会议日程

Editorial - 编者按 p.3

Scientific committee - 科学委员会 p.4-5

Program - 会议日程 p.6

September 1, 2018 - 2018年9月1日 p.6

September 2, 2018 - 2018年9月2日 p.11

Posters - 海报展示 p.16

Congress venue - 会场地点 p.18

Sponsors - 赞助商 p.18

SU

MM

AR

Y -

目录

Gra

phic

des

igne

r: K

om G

raph

ik

2018 1ST CTAD ASIA-CHINA CONFERENCE

3PROGRAM - 会议日程

Editorial编者按

The goal of the 1st CTAD Asia -China Conference is to bring together Asian leaders on the treatment and management of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues that are essential to the development of the next generation of Alzheimer’s disease treatments.

第一届CTAD亚洲-中国大会的目标是召集阿尔茨海默氏病治疗和管理方面的亚洲领导者，探讨对开发新型阿尔茨海默氏病疗法至关重要的新成果、候选疗法和方法论问题。

Since 2008, The Clinical Trials on Alzheimer’s Disease Conference (CTAD) has held an annual eventfocused on the development of the next generation of Alzheimer’s disease treatments. Alzheimer’s disease is among the most important health needs worldwide, but presents huge challenges.

自2008年以来，阿尔茨海默病临床试验会议（CTAD）每年举办一次，专注于下一代阿尔茨海默病治疗的发展。阿尔茨海默病是全球最重要的健康需求之一，但却带来了巨大的挑战。

This 1st CTAD Asia - China Conference will focus largely on how to develop successful AD clinical trials worldwide through conferences on important topics for conducting clinical trials: methodology, database management of clinical trials, biomarkers, patient recruitment, etc.

第一届CTAD亚洲-中国大会将重点关注如何通过举办有关临床试验重要课题的研讨会，在全球范围内成功开展阿尔茨海默氏病的临床试验。这些课题包括：方法论、临床试验的数据库管理、生物标志物、患者招募等。

We are delighted to be welcoming you to Shanghai!

我们期待与您在上海会面！

On behalf of the CTAD Asia-China Organizing Committee

谨代表CTAD亚洲-中国大会组委会

4 PROGRAM - 会议日程

Scientific committee (in alphabetical order)科学委员会成员（按字母顺序排列)

Hidenori Arai, MD, PhDDeputy Director, National Center for Geriatrics and Gerontology – Director, Center for Gerontology and Social Science, Tokyo, Japan荒井秀典，医学博士和哲学博士国立长寿医疗研究中心副主任——老年学和社会科学研究中心主任，日本东京 Paul Aisen, MDAlzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San DiegoPaul Aisen, 医学博士圣地亚哥南加州大学阿尔茨海默氏病治疗研究所 Piu Chan, MD, PhDProfessor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China陈彪，医学博士和哲学博士北京老年医学研究所教授和主任、首都医科大学宣武医院神经内科、神经生物学科、老年医学科主任医师，国家GCP（药物临床试验管理规范）神经退行性疾病临床试验中心的教授和主任，中国北京

Kewei Chen, PhD Sr. Scientist and Sr. Bio-mathematician Director of Core Resources, Neuroimaging Research and Analysis Lab. Banner Alzheimer’s Institute, Banner Health Director, Data Management & Statistics Core (DMSC) The Arizona Alzheimer’s Disease Core Center (ADCC) National Alzheimer’s Coordinating Center (NACC) Research Professor, Dept. of Neurology, College of Medicine-Phoenix, Univ. of Arizona ; ASU School of Mathematics and Statistics ; Beijing Normal University; Med-X Institute, Shanghai Jiao Tong University陈克伟，哲学博士资深科学家和生物数学家， Banner健康中心Banner阿尔茨海默氏病研究所神经影像数据研究与分析实验室核心资源主任，美国国家阿尔茨海默氏病协调中心（NACC）亚利桑那州分中心（ADCC）的数据管理与统计分析部（DMSC）主任、亚利桑那大学菲尼克斯医学院神经内科、亚利桑那州立大学数学和统计学院、北京师范大学、上海交通大学Med-X 研究院研究教授

Liang-Kung Chen, MD, PhDDirector, Center for Geriatrics and Gerontology, Taipei Veterans General HospitalProfessor and Director, Aging and Health Research Center, National Yang Ming UniversityPresident, Taiwan Association of Integrated Care, Taiwan陈亮恭，医学博士和哲学博士台北荣民总医院高龄医学中心主任，国立阳明大学高龄与健康研究中心教授兼主任，台湾整合照护协会主席——台湾

Jeffrey L. Cummings, M.D., Sc.DCamille and Larry Ruvo Chair for Brain Health Director, Cleveland Clinic Lou Ruvo Center for Brain Health Director, Center for Neurodegeneration and Translational Neuroscience Professor, Cleveland Clinic Lerner College of Medicine Las Vegas, Nevada – USAJeffrey L. Cummings，医学博士和理学博士Camille and Larry Ruvo脑健康中心主任，Cleveland Clinic Lou Ruvo脑健康中心主任，美国内华达州拉斯维加斯的Cleveland Clinic Lerner医学院神经退行性疾病和转化神经科学中心教授

Rachelle Doody, MD, PhDGlobal Head of Neurodegeneration, Roche, Basel, SwitzerlandRachelle Doody，医学博士和哲学博士罗氏公司神经退行性疾病全球负责人，瑞士巴塞尔

Lei Feng, MDPrincipal Investigator & Research Assistant Professor Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore - Singapore封磊，医学博士新加坡国立大学杨潞龄医学院心理医学系首席研究员兼助理研究教授，新加坡

Phyllis Barkman FerrellAD Platform Vice President and Global Business Development Leader, Eli Lilly & Company, Indianapolis - USAPhyllis Barkman FerrellEli Lilly & Company阿尔茨海默氏病平台副总裁兼全球业务发展负责人，美国印第安纳波利斯

Meiyu Geng, MD, PhDProfessor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China耿美玉，医学博士和哲学博士中国科学院上海药物研究所教授，首席研究员，中国上海

Jingping Jia, MD, PhD Xuan Wu Hospital, Capital Medical University, Key Laboratory of Geriatric Cognitive Disorders, Center of Alzheimer’s Disease, Institute for Brain Disorders, Key Laboratory of Neurodegenerative Diseases, National Clinical Research Center for Geriatric Disorders, Beijing, China贾建平，医学博士和哲学博士首都医科大学宣武医院老年认知障碍重点实验室，阿尔茨海默氏病中心，脑疾病研究所，神经退行性疾病重点实验室，国家老年疾病临床医学研究中心，中国北京

Jun Li MD, PhDDepartment of Geriatrics, Center of Gerontology and Geriatrics, Department of Geriatrics, West China Hospital of Sichuan University, Chengdu, China李峻，医学博士和哲学博士四川大学华西医院老年科老年医学中心，中国成都

Reshma Merchant MD, PhD Head, Division of Geriatric Medicine, National University Hospital, SingaporeReshma Merchant，医学博士和哲学博士新加坡国立大学医院老年医学部主任，新加坡

So Young Moon, MD, PhDDepartment of Neurology, School of Medicine, Ajou University, Suwon, South KoreaSo Young Moon，医学博士和哲学博士亚洲大学医学院神经内科，韩国水原市

Ivana Rubino, MDSenior Medical Director, Alzheimer’s Disease Leader, Biogen, Boston MA - USAIvana Rubino，医学博士Biogen公司阿尔茨海默氏病负责人兼高级医疗总监，美国马萨诸塞州波士顿



ST CTAD ASIA-CHINA CONFERENCE 1ST CTAD ASIA-CHINA CONFERENCE

Takashi Sakurai MD, PhDCenter for Comprehensive Care and Research on Memory Disorders, National Center for Geriatrics and Gerontology, Obu City, Aichi Prefecture, JapanTakashi Sakurai，医学博士和哲学博士任职于日本爱知县大府市日本国立长寿医疗研究中心记忆障碍与综合护理研究中心

Jiong Shi MD, PhDFAANProfessor, Department of Neurology, Barrow Neurological Institute, Phoenix, USA施炯，医学博士和哲学博士医学博士与哲学博士, 圣约瑟医院与医疗中心, 美国亚利桑那州凤凰城

Jacques Touchon, MD, PhDMontpellier School of MedecineINSERM U1061Jacques Touchon，医学博士和哲学博士蒙彼利埃大学医学院 -法国国家健康与医学研究院U1061实验室

Bruno Vellas, MD, PhDChair of the Gerontopole & Department of Geriatric Internal Medicine at the Toulouse University Hospital Member of the INSERM UMR 1027, adjunct professor at the Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA, Chair of the WHO Collaborating Center for Frailty, Clinical Research and Geriatric Training since September 2017Bruno Vellas，医学博士和哲学博士图卢兹大学医院老年医学和老年内科系主任、法国国家健康与医学研究院UMR 1027实验室成员、美国新墨西哥州阿尔伯克基市新墨西哥大学内科系客座教授，自2017年9月起担任世界卫生组织虚弱人士、临床研究与老年培训合作中心主任 Ninie WangCEO, Pinetree Care Group, Beijing, China王燕妮中国北京青松康复护理首席执行官

Jin-Tai Yu, MD, PhD Assistant President of Hospital Director, Clinical Research Center Vice Chairman, Department of Neurology, Professor of Neurology Qingdao Municipal Hospital, Qingdao University Qingdao, China郁金泰，医学博士和哲学博士中国青岛大学青岛市立医院院长助理、临床研究中心主任、神经内科教授

Jing Zhang, M.D., Ph.D. Professor of Pathology, Shaw Endowed Chair in Neuropathology, Adjunct Professor of Neurology, Ophthalmology and Oral Health Sciences, University of Washington School of Medicine - Seattle, WA章京，医学博士和哲学博士美国华盛顿州西雅图华盛顿大学医学院神经病理科冠名讲席教授(Shaw Endowed Chair),神经内科、眼科与口腔卫生科学、客座教授

Zheng-Xin Zhang, M.D., Ph.D. Departments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, China Beijing Brain Health Center, Beijing, China 张振馨，医学博士和哲学博士中国医学科学院北京协和医院神经内科、中国北京脑健康中心

Kate Zhong, M.D., MSc, FRCPCSO Global Alzheimer’s Platform Foundation Washington, DC - USAKate Zhong，医学博士、理学硕士、皇家内科医师学会会员全球阿尔茨海默氏症平台基金首席战略官，美国华盛顿

Scientific committee (in alphabetical order)科学委员会成员（按字母顺序排列)


PROGRAMSaturday, September 1

8:45 - 9:00 am Opening Ceremony

开幕式

9:00 - 9:20 am CONFERENCE 会议Chair: Bruno Vellas 主席：Bruno Vellas

2018 Alzheimer Disease PipelineJeffrey L Cummings, MD Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada

2018年阿尔茨海默氏病新药研发Jeffrey L Cummings，医学博士由NHI/NIGMS资助的Cleveland Clinic Lou Ruvo脑健康中心神经退行性疾病和转化神经科学医疗中心的首席研究员/主任，内华达拉斯维加斯

9:20 - 9:40 am CONFERENCE 会议Chairs: Piu Chan and Bruno Vellas 主席：陈彪和Bruno VellasClinical trials of prodromal AD in China: clinical environment and research resourcesZheng-Xin Zhang, MD, PhDDepartments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing Brain Health Center, Beijing, China

中国的前驱期AD临床试验：临床环境和研究资源张振馨，医学博士和哲学博士中国医学科学院北京协和医院神经内科、脑健康中心，中国北京

9:40 - 10:00 am CONFERENCE 会议Chairs: Piu Chan and Bruno Vellas 主席：陈彪和Bruno VellasAlzheimer’s therapeutic research: what are our prospects?Paul Aisen, MD, PhDDirector Alzheimer Therapeutic Research Institute, University of Southern California, San Diego, USA

阿尔茨海默氏病治疗研究：我们的前景如何？Paul Aisen，医学博士和哲学博士南加州大学阿尔茨海默氏病治疗研究所所长，美国圣地亚哥

10:00 - 10:30 am Coffee break and poster sessions - 茶歇和海报环节

10:30 - 1:00 pm ORAL COMMUNICATIONS 口头报告Chairs: Kewei Chen and Paul Aisen 主席：陈克伟和Paul Aisen

10:30 - 10:45 am OC1: Baseline characteristics from a Phase III trial of crenezumab in prodromal-to-mild Alzheimer’s disease (CREAD)Helen Lin, MD (1), Susanne Ostrowitzki, MD, PhD (1), Kaycee M. Sink, MD, MAS (1), Laurie Millar, PhD (2), Francis Warren, PhD (2), Jillian Smith, BSc (2), Andres Schneider, MD (3), Reina N. Fuji, VMD, PhD (1), Angelica Quartino, PhD (1), Howard Mackey, PhD (1), Michael Rabbia, MA (4), Susan Yule, B. Pharm (3), Paulo Fontoura, MD, PhD (3), Rachelle Doody, MD, PhD (1,3)(1) Genentech, Inc. – South San Francisco, CA, US, (2) Roche Products Ltd – Welwyn Garden City, UK, (3) F. Hoffmann-La Roche Ltd – Basel, Switzerland, (4) Genentech, Inc. – Little Falls, NJ, US

OC1 : Crenezumab对前驱到中度阿尔兹海默氏病（CREAD）III期临床试验的基线特征Helen Lin, 医学博士(1), Susanne Ostrowitzki, 医学博士和哲学博士(1), Kaycee M. Sink, 医学博士和会计理学硕士(1), Laurie Millar, 哲学博士(2), Francis Warren, 哲学博士(2), Jillian Smith, 理学学士(2), Andres Schneider, 医学博士(3), Reina N. Fuji, 兽医学博士和哲学博士(1), Angelica Quartino, 哲学博士(1), Howard Mackey, 哲学博士(1), Michael Rabbia, 文学硕士(4), Susan Yule, 药学学士(3), Paulo Fontoura, 医学博士和哲学博士(3), Rachelle Doody, 医学博士和哲学博士(1,3) (1) 基因工程技术公司（Genentech,Inc.）– 美国加州南旧金山 (2) 罗氏产品有限公司（Roche Products Ltd） – 英国韦林花园市 (3) F. Hoffmann-La Roche Ltd – 瑞士巴塞尔 (4) 基因工程技术公司（Genentech,Inc.） – 美国新泽西州小瀑布市

会议日程 9月1日星期六

*all chairpersons to be confirmed *所有会议主席待定




ORAL COMMUNICATIONS 口头报告Chairs: Kewei Chen and Paul Aisen 主席：陈克伟和Paul Aisen

10:45 - 11:00 am OC2: Cognitive evaluation of treatment effects of the bromodomain and extraterminal domain inhi-bitor apabetalone; Design and baseline data of the cognition substudy of the BETonMACE Phase 3

cardiovascular trialJ. Cummings (1), J. Johansson (2), E. Kulikowski (3), N.C. Wong (3), C. Halliday (3), K. Lebioda (3), B. Winblad (4), H. Zetterberg (5), K. Kalantar-Zadeh (6), S.J. Nicholls (7), G.G. Schwartz (8), K.K. Ray (9), M. Sweeney (2)(1) Cleveland Clinic Lou Ruvo, Center for Brain Health, Las Vegas, USA, (2) Resverlogix Corp., Research and Deve-lopment, San Francisco, USA, (3) Resverlogix Corp., Research and Development, Calgary, Canada, (4) Karolinska Ins-titute, Department of NVS, Division of Neurogeriatrics, Huddinge, Sweden, (5) Sahlgrenska Academy at the University of Gothenburg, Department of Psychiatry and Neurochemistry- Institute of Neuroscience and Physiology, Gothenburg, Sweden, (6) School of Medicine, Division of Nephrology & Hypertension, Irvine, USA, (7) University of Adelaide, South Australian Health & Medical Research, Adelaide, Australia, (8) University of Colorado, School of Medicine, Denver, USA, (9) Imperial College, Department of Primary Care and Public Health, London, United Kingdom

OC2 : 溴结构域与额外末端结构域抑制apabetalone治疗效果的认知评估；BETonMACE三期心血管试验认知亚组研究的设计与基线数据 J. Cummings (1), J. Johansson (2), E. Kulikowski (3), N.C.Wong (3), C. Halliday (3), K. Lebioda (3), B. Winblad (4), H. Zetterberg (5), K. Kalantar-Zadeh (6), S.J.Nicholls (7), G.G.Schwartz (8), K.K.Ray (9), M. Sweeney (2)(1) Cleveland Clinic Lou Ruvo, 脑部健康中心, 美国拉斯维加斯 (2) Resverlogix Corp., 研究与开发, 美国旧金山 (3) Resverlogix Corp., 研究与开发, 加拿大卡尔加里 (4)卡罗林斯卡学院, 神经病学体征科, 老年神经病学系, 瑞典胡丁厄 (5)哥德堡大学Sahlgrenska学院, 精神病与神经化学系- 神经科学与心理学学院, 瑞典哥德堡 (6)医学院, 肾脏学与高血压系, 美国欧文 (7)阿德莱德大学, 南澳大利亚健康与医学研究, 澳大利亚阿德莱德 (8)科罗拉多大学, 医学院, 美国丹佛 (9)帝国学院, 初级保健与公共卫生系, 英国伦敦

11:00 - 11:15 am OC3: Chinese version of the Baylor Profound Mental Status ExaminationXue Fu, MM (1), Meiling Ke, MM (2), Weihua Yu, MD, PhD (2), Xia Wang, MM (1), Qian Xiao, MM (1), Min Gu, MM (1), Jia Zhang, MD, PhD (1), Tao Luo, MD, PhD (1), Paul J. Massman, MD, PhD (3,4), Rachelle S. Doody, MD, PhD (3), Yang Lü, MD, PhD (1)(1) Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing China, (2) Institute of Neuroscience, Chongqing Medical University, Chongqing, China, (3) Department of Neurology, Baylor College of Medicine, Houston, TX USA at the time this work was done. Now Genentech/Roche, Basel, Switzerland, (4) Department of Psychology, University of Houston, Houston, TX USA

OC3 : 贝勒深刻精神状态考试中文版 Xue Fu, 医学硕士 (1), Meiling Ke, 医学硕士(2), Weihua Yu, 医学博士, 哲学博士(2), Xia Wang, 医学硕士(1), 肖谦, 医学硕士(1), Min Gu, 医学硕士(1), 张佳, 医学博士, 哲学博士(1), 罗涛, 医学博士,哲学博士(1), Paul J. Massman, 医学博士, 哲学博士(3,4), Rachelle S. Doody, 医学博士后, 哲学博士(3), 吕洋, 医学博士, 哲学博士(1)(1)重庆医科大学第一附属医院老年病科，中国重庆 (2) 重庆医科大学神经病学研究所, 中国重庆 (3)贝勒医学院神经病科, 美国得克萨斯州休斯顿（本项目进行时）现为Genentech/罗氏，瑞士巴塞尔，(4)休斯顿大学神经病系, 美国德克萨斯州休斯顿

11:15 - 11:30 am OC4: Consortium for dementia prevention in Chinese populations (CDPCP): a proposed platform for information-sharing and research collaborations Lei Feng, MD, PhD (1), Juan Li, PhD (2), Jin-Tai Yu, MD, PhD (3), Can Zhang, MD, PhD (4), Chunbo Li, MD, PhD (5), Bruno Vellas, MD, PhD (6)(1) Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singa-pore, (2) Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, Shandong, China, (3) Institute of Psychology, the Chinese Academy of Sciences, Beijing, China, (4) Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, U.S.A, (5) Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, (6) Department of Geriatric & Internal Medicine, Toulouse University, France

OC4 : 中国人口老年痴呆预防联盟（CDPCP）：拟建的信息共享与研究协作平台封磊, 医学博士和哲学博士(1), 李娟, 哲学博士(2), 郁金泰, 医学博士和哲学博士(3), Can Zhang, 医学博士和哲学博士(4), 李春波, 医学博士和哲学博士(5), Bruno Vellas, 医学博士和哲学博士(6)(1) 新加坡国立大学杨潞龄医学院心理医学系, 新加坡 (2)青岛市市立医院神经病科, 青岛大学, 中国山东青岛 (3)中国科学院心理学研究所, 中国北京 (4)马萨诸塞州综合医院与哈佛医学院神经病系, 美国波斯顿(5)上海心理疾病重点实验室, 上海精神卫生中心, 上海交通大学医学院, 中国上海 (6)图卢兹大学老年病与内科系，法国






11:30 - 11:50 am CONFERENCE 会议Chair: Kate Zhong 主席：Kate Zhong

China Neuroimaging Initiative on Parkinson’s disease and Alzheimer’s diseasePiu Chan, MD, PhDProfessor and Director, Beijing Institute of Geriatrics, Department of Neurology, Neurobiology and Geriatrics, Xuanwu Hospital of Capital Medical University, National GCP Clinical Trial Center on Neurodegenerative Diseases, Beijing, China中国帕金森病和阿尔茨海默病神经影像学计划陈彪，医学博士和哲学博士北京老年医学研究所教授兼主任、首都医科大学宣武医院神经内科、神经生物学科、老年医学科主任医师,国家GCP（药物临床试验管理规范）神经退行性疾病临床试验中心教授兼主任

12:00 - 1:00 pm Lunch - 午餐

1:00 - 2:00 pm PANEL DISCUSSION 小组讨论Operational aspects of Clinical Trials in Alzheimer’s Disease: High level opportunities and ChallengesKate Zhong, MD, MSc, FRCPCSO Global Alzheimer’s Platform Foundation Washington, DC - USA

阿尔茨海默氏病临床试验的运行情况：高层次机会与挑战Kate Zhong，医学博士和理学硕士，皇家内科医师学会会员全球阿尔茨海默氏病平台基金首席战略官，美国华盛顿

The US experiencePaul Aisen, MD, PhDDirector Alzheimer Therapeutic Research Institute, University of Southern California, San Diego, USA

美国经验Paul Aisen，医学博士和哲学博士南加州大学阿尔茨海默氏病治疗研究所所长，美国圣地亚哥

Experience of a Chinese Pharmaceutical LabMeiyu Geng, MD, PhDProfessor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Main investigator Shanghai Green Valley

一家中国药物实验室的经验耿美玉，医学博士和哲学博士中国科学院上海药物研究所教授兼首席研究员，中国上海上海绿谷制药主要研究员

Implementing global clinical trials in China and the potential of technology to improve implementationAmir Kalali MDExecutive Advisor, Bracket Global, San Diego , USA

在中国实施全球临床试验以及技术提升实施的潜力Amir Kalali，医学博士执行顾问，Bracket Global（美国圣地亚哥）

Experience from a US Pharmaceutical labSamantha Budd Haeberlein, PhDPresident of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA

一家美国药物实验室的经验Samantha Budd Haeberlein, 哲学博士 Biogen阿尔茨海默氏病发现与发展总裁，美国波士顿 Point of view of a Chinese HospitalZheng-Xin Zhang, MD, PhDDepartments of Neurology, Peking Union Medical College Hospital, and Chinese Academy of Medical Sciences, Beijing Brain Health Center, Beijing, China

一家中国医院的观点张振馨，医学博士和哲学博士中国医学科学院北京协和医院神经内科、脑健康中心，中国北京





2:00 - 2:20 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰Pathogenesis and Treatment of AD: Why start with targeting amyloid and tau protein?Rachelle Doody, MDGlobal Head of Neurodegeneration, Roche, Basel – SwitzerlandAD的发病机制和治疗：为什么要从针对淀粉样蛋白和tau蛋白着手？Rachelle Doody，医学博士巴塞尔罗氏公司神经退行性疾病全球负责人，瑞士

2:20 - 2:40 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰

Evidence-Based Prevention of Alzheimer’s DiseaseJin-Tai Yu, MD, PhD Professor in the department of Neurology, Director of the Clinical Research Center in Qingdao Municipal Hospital, Qing-dao University阿尔茨海默氏病的循证预防郁金泰，医学博士和哲学博士神经内科教授，青岛大学青岛市市立医院临床研究中心主任

2:40 - 3:00 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰Alzheimer’s Research – A story of resilience, collaboration, learning, and informed hopePhyllis Barkman FerrellVice President, Global Alzheimer’s Disease Platform Team, Eli Lilly & Company, Indianapolis, IN – USA阿尔茨海默氏症的研究——一个关于复原力、合作、学习和可靠的希望的故事Phyllis Barkman Ferrell礼来公司全球阿尔茨海默氏病平台团队副总裁，美国印第安纳波利斯

3:00 - 3:30 pm Coffee break and poster sessions - 茶歇和海报环节

3:30 - 3:50 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰The Impairment of Cognition Study (ICONS) from China National Stroke Registry IIIJiong Shi, MD, PhDDepartment of Neurology at Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center, Phoenix, AZ – USA第三次中国国家卒中登记的认知障碍研究（ICONS）施炯, 医学博士与哲学博士圣约瑟医院与医疗中心, 美国亚利桑那州凤凰城

3:50 - 4:10 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰Clinical trials on the management of agitation and other behavioral disordersJeffrey L Cummings, MD Principal Investigator/Director of the NIH/NIGMS-funded Center for Neurodegeneration and Translational Neuroscience at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada有关焦虑和其他行为障碍管理的临床试验Jeffrey L Cummings，医学博士由NHI/NIGMS资助的Cleveland Clinic Lou Ruvo脑健康中心神经退行性疾病和转化神经科学医疗中心的首席研究员/主任，内华达拉斯维加斯






4:10 - 4:30 pm CONFERENCE 会议Chairs: Jiong Shi and Jin-Tai Yu 主席：施炯和喻金泰How to translate the newest science into the most innovative and useful therapeutics for AD through clinical trials” (to be confirmed)Can (Martin) Zhang, M.D.,Ph.DAssistant Professor of Neurology, Harvard Medical School, Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Boston, MA – USA如何通过临床试验将最新科研成果转化为最具创新性和最有效的AD治疗方法（待定）Can (Martin) Zhang，医学博士和哲学博士哈佛医学院神经病学助理教授，麻省总医院神经退行性疾病研究所遗传与衰老研究部，麻省总医院神经内科，美国马萨诸塞州波士顿




PROGRAMSunday, September 2 9月2日星期日

8:40 - 9:00 am CONFERENCE 会议Chair: Jacques Touchon 主席：Jacques TouchonDementia in China: Prevalence, Costs, and Clinical trialsJingping Jia, MD, PhDDepartment of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, China; Beijing Key Laboratory of Geria-tric Cognitive Disorders, Beijing, China; Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing, China; Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; National Clinical Research Center for Geriatric Disorders, Beijing, China中国痴呆症：发病率、费用和临床试验贾建平，医学博士和哲学博士首都医科大学宣武医院，老年认知障碍重点实验室，阿尔茨海默氏病中心，脑疾病研究所，神经退行性疾病重点实验室，国家老年疾病临床医学研究中心，中国北京

9:00 - 10:30 am TRANSFORMING AD IN CHINA: FROM DIAGNOSIS TO TREATMENT中国对AD的诊治：从诊断到治疗1. Complex problem, complete solution: Why we need to tackle AD from all angles

Prof. Jeff Cummings, Cleveland Clinic, Las Vegas, USA (Chair)

复杂的问题，完整的解决方案：为什么我们需要全方位应对AD? Jeffrey Cummings教授，克利夫兰医学中心，美国拉斯维加斯（会议主席） 2. Emerging roles of biomarkers in AD

Prof. Eric Reiman, Banner Alzheimer’s Institute, Phoenix, USA

生物标志物在AD中的新角色 Eric Reiman教授，班纳阿尔茨海默氏病研究所，美国凤凰城

3. Use of biomarkers in real-world practice to diagnose AD in China Prof. Zhenxin Zhang, Peking Union Medical College Hospital, Beijing, China

生物标志物在中国AD诊断中的实际应用张振馨教授，北京协和医院，中国北京4. The clinical picture of dementia

Prof. Andreas Monsch, Head of Memory Clinic, Basel, Switzerland

痴呆症的临床特征 Andreas Monsch教授，记忆诊所负责人，瑞士巴塞尔

5. Neuropsychiatric features in differential diagnosis of AD in China Prof. Huali Wang, Peking University Institute of Mental Health, Beijing, China

中国AD鉴别诊断中的神经精神病学特征王华丽教授，北京大学精神卫生研究所，中国北京

6. Roche in AD: Commitment, experience, and development program Dr Rachelle Doody, Roche, Basel, Switzerland

罗氏公司在AD方面的成就：承诺、经验和发展计划 Rachelle Doody博士，罗氏公司，瑞士巴塞尔

10:30 - 11:00 am Coffee break and poster sessions - 茶歇和海报环节

11:00 - 11:20 am CONFERENCE 会议Chair: Jacques Touchon 主席：Jacques TouchonDrug Development ChallengesSamantha Budd Haeberlein, PhDPresident of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA药物开发挑战Samantha Budd Haeberlein, 哲学博士 Biogen阿尔茨海默氏病发现与发展总裁，美国波士顿

会议日程



PROGRAMSunday, September 2

11:20 - 12:20 pm ORAL COMMUNICATIONS 口头报告Chairs: Jeffrey Cummings and Meiyu Geng 主席： Jeffrey Cummings和耿美玉

11:20 - 11:35 am OC5: Prevalence of neuropsychiatric symptoms in patients with cognitive impairment: results from a memory clinicXia Wang, MS (1), Yang Lü, PhD (1)(1) Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

OC5 : 有认知障碍病人的神经精神病学症状发病率：来自一个记忆门诊的结果 Xia Wang，理科硕士(1), Yang Lü, 哲学博士(1)(1) 重庆医科大学第一附属医院老年病科，中国重庆

11:35 - 11:50 am OC6: Safety, tolerability and pharmacokinetics of crenezumab in mild-to-moderate AD patients treated with escalating doses for up to 32.3 months Helen Lin, MD (1), Andres Schneider, MD (2), Angelica Quartino, PhD (1), Tobias Bittner, PhD (2), Nan Hu, PhD (1), Jillian Smith, BSc (3), William Cho, MD (1), Susanne Ostrowitzki, MD, PhD (1)(1) Genentech, Inc. – South San Francisco, CA, US, (2) F. Hoffmann-La Roche AG – Basel, Switzerland, (3) F. Hoff-mann-La Roche Ltd – Basel, Switzerland

OC6 : Crenezumab对最长32.3个月内以递增剂量治疗的轻度至中度AD病人的安全性、耐受性和药物代谢动力学 Helen Lin, 医学博士(1), Andres Schneider, 医学博士(2), Angelica Quartino, 哲学博士(1), Tobias Bittner, 哲学博士(2), Nan Hu, 哲学博士(1), Jillian Smith, 理学学士(3), William Cho, 医学博士(1), Susanne Ostrowitzki, 医学博士和哲学博士(1)(1) Genentech公司 – 美国加州南旧金山 (2) F. Hoffmann-La Roche AG – 瑞士巴塞尔 (3) F. Hoffmann-La Roche Ltd – 瑞士巴塞尔

11:50 - 12:05 pm OC7: Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzhei-mer’s disease: a network meta-analysis of 41 randomized controlled trialsKai-Xin Dou, MD (1), Meng-Shan Tan, MD (1), Chen-Chen Tan, MD, PhD (1), XiPeng Cao, MS (2), Xiao-He Hou (1), Qi-Hao Guo, MD (3), Lan Tan, MD, PhD (1), Vincent Mok, MD (4,5,6), Jin-Tai Yu, MD, PhD (1,2)*(1) Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China, (2) Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China, (3) Department of Neurology & Institute of Neurology, Huashan Hospital, Fudan University, WHO Collaborating Center for Research and Training in Neuros-ciences, Shanghai, China, (4) Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China, (5) Therese Pei Fong Chow Research Center for Prevention of Dementia, The Chinese University of Hong Kong, Hong Kong, China, (6) Gerald Choa Neuroscience Centre, Lui Che Woo Institute of Innovative Medicine, The Chinese University of Hong Kong, Hong Kong, China

OC7 : 胆碱酯酶抑制剂和美金刚胺对阿尔茨海默氏病的相对安全性和效果：对41个随机对照试验的网络汇总分析 Kai-Xin Dou, 医学博士(1), Meng-Shan Tan, 医学博士(1), Chen-Chen Tan, 医学博士, 哲学博士(1), XiPeng Cao, 理科硕士(2), Xiao-He Hou(1), 郭起浩, 医学博士(3), 谭兰, 医学博士与哲学博士(1), Vincent Mok, 医学博士(4,5,6), 郁金泰, 医学博士与哲学博士(1,2)*(1) 青岛市市立医院神经内科、青岛大学, 中国青岛 (2) 青岛市市立医院临床研究中心、青岛大学, 中国青岛 (3) 华山医院精神内科与精神病学研究所、复旦大学、WHO上海精神卫生研究和培训合作中心, 中国上海 (4)香港中文大学医学院内科及药物治疗学系神经内科，中国香港5香港中文大学周佩芳认知障碍预防研究中心，中国香港 (6) 香港中文大学蔡永业脑神经科学中心、吕志和创新医学研究所，中国香港

12:05 - 12:20 pm OC8: Models for predicting risk of dementia: A systematic reviewXiao-He Hou, MD, PhD (1), Lei Feng, MD, PhD (2), Can Zhang, MD, PhD (3), Xi-Peng Cao, MS (4), Lan Tan, MD, PhD (1), Jin-Tai Yu, MD, PhD (1,4)(1) Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China, (2) Department of Psy-chological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, (3) Genetics and Aging Research Unit, Mass General Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Mas-sachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA, (4) Clinical Research Center, Qingdao Municipal Hospital, Qingdao University, Qingdao, China

OC8 : 痴呆症风险预测模型：系统性评价Xiao-He Hou, 医学博士与哲学博士(1), 封磊, 医学博士与哲学博士(2), Can Zhang, 医学博士与哲学博士(3), Xi-Peng Cao, 理科硕士(4), 谭兰, 医学博士与哲学博士(1), 郁金泰, 医学博士与哲学博士(1,4)(1) 青岛市市立医院精神内科、青岛大学，中国青岛 (2) 新加坡国立大学杨潞龄医学院心理医学系 (3) 马萨诸塞州综合医院精神内科大众神经退行性疾病研究所（MIND）基因与老化研究组，美国马萨诸塞州查尔斯顿 (4) 青岛市市立医院临床研究中心、青岛大学，中国青岛。

12:20 - 1:20 pm Lunch - 午餐

9月2日星期日会议日程





1:20 - 1:40 pm CONFERENCE 会议Chairs: Yong Shen and Zheng-Xin Zhang 主席：申勇和Zheng-Xin ZhangMolecular mechanisms of GV-971 against Alzheimer’s diseaseMeiyu Geng, MD, PhDProfessor and Principal investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.Main investigator Shanghai Green ValleyGV-971对抗阿茨尔海默氏病的分子机制耿美玉，医学博士和哲学博士中国科学院上海药物研究所教授兼首席研究员，中国上海上海绿谷制药主要研究员

1:40 - 2:00 pm CONFERENCE 会议Chairs: Yong Shen and Zheng-Xin Zhang 主席：申勇和Zheng-Xin ZhangAlzheimer’s clinical studies and trials in Japan and Asia: opportunities for future collaborationsTakeshi Iwatsubo, MDProfessor, The University of Tokyo, Faculty of Medicine, Tokyo, Japan阿尔茨海默氏病在日本和亚洲的临床研究和试验:未来合作的机会Takeshi Iwatsubo，医学博士日本东京大学医学院教授，日本东京

2:00 - 4:15 pm ORAL COMMUNICATIONS 口头报告Chairs: Jeffrey Cummings and Meiyu Geng 主席： Jeffrey Cummings和耿美玉

2:00 - 2:15 pm OC9: Optimizing the gantenerumab Phase III dosing regimen through PK/PD modeling and clinical

trial simulationsCarsten Hofmann, PhD (1), Ronald Gieschke, MD, PhD (1), Sylvie Retout PhD (1), Smiljana Ristic, MD (2), Nicola Voyle, PhD (3), Paul Delmar, PhD (2), Daniel Serafin, PhD (1)(1) Clinical Pharmacology and Bioanalytical R&D, Roche Pharma Research and Early Development – Basel, Switzer-land, (2) Neuroscience, Roche Product Development – Basel, Switzerland, (3) Neuroscience, Roche Product Develop-ment – Welwyn, UK

OC9 : 通过PK/PD建模和临床试验模拟优化gantenerumab三期给药方案 Carsten Hofmann, 哲学博士(1), Ronald Gieschke, 医学博士与哲学博士(1), Sylvie Retout 哲学博士(1), Smiljana Ristic, 医学博士(2), Nicola Voyle, 哲学博士(3), Paul Delmar, 哲学博士(2), Daniel Serafin, 哲学博士(1)(1) 临床药理学和生物分析研发、罗氏医药研究和早期开发 – 瑞士巴塞尔 (2) 精神科学，罗氏产品开发 – 瑞士巴塞尔 (3) 罗氏产品开发，精神病学 – 英国韦林

2:15 - 2:30 pm OC10: Strategy of Research New Drugs Against ADCuibai Wei (1) MD, PhD, Jianping Jia (1) MD, PhD, Jihui Lv (2) MD, PhD, Yujing Zhang (1) MD(1) Neurology Department, Xuan Wu Hospital, Capital Medical University, Beijing, China, (2) Neurology Department, Beijing Geriatric Hospital, Beijing, China

OC10 : 抗AD新药研究策略魏翠柏(1) 医学博士与哲学博士, 贾建平(1) 医学博士与哲学博士, 吕继辉(2) 医学博士与哲学博士, Yujing Zhang(1) 医学博士(1) 首都医科大学宣武医院神经内科，中国北京 (2) 北京老年医院神经内科，中国北京

2:30 - 2:45 pm OC11: 24-month amyloid PET results of the gantenerumab high-dose, open-label extension studies Gregory Klein, PhD (1), Paul Delmar PhD (2), Carsten Hofmann, PhD (1), Danielle Abi-Saab, PsyD (2), Mirjana Andjel-kovic, PhD (2), Smiljana Ristic, MD (2), Nicola Voyle, PhD (3), John Seibyl (4), Ken Marek (4), Ferenc Martenyi, MD (2), Monika Baudler, PhD (2), Paulo Fontoura, MD, PhD (2), Rachelle Doody, MD, PhD (2)(1) Roche Pharma Research and Early Development – Basel, Switzerland, (2) Roche / Genentech Product Develop-ment, Neuroscience – Basel, Switzerland, (3) Roche Products Ltd – Welwyn Garden City, UK, (4) InviCRO, LLC – Bos-ton, MA, US

OC11 : Gantenerumab高剂量、开放标签扩展研究的24个月淀粉样蛋白PET结果 Gregory Klein, 哲学博士(1), Paul Delmar 哲学博士(2), Carsten Hofmann, 哲学博士(1), Danielle Abi-Saab, 心理学博士(2), Mirjana Andjelkovic, 哲学博士(2), Smiljana Ristic, 医学博士(2), Nicola Voyle, 哲学博士(3), John Seibyl(4), Ken Marek(4), Ferenc Martenyi, 医学博士(2), Monika Baudler, 哲学博士(2), Paulo Fontoura, 医学博士与哲学博士(2), Rachelle Doody, 医学博士与哲学博士(2)(1) 罗氏药物研究与早期开发 – 瑞士巴塞尔 (2) 罗氏/Genentech 产品开发, 神经科学– 瑞士巴塞尔 (3) 罗氏产品有限公司– 英国韦林花园市 (4) InviCRO, LLC – 美国马萨诸塞州波士顿

会议日程



PROGRAMSunday, September 2

2:00 - 4:15 pm ORAL COMMUNICATIONS 口头报告2:45 - 3:00 pm OC12: Partial Performance Improvement of Patients with Severe Alzheimer’s Disease at Early

Stages of Fornix Deep Brain StimulationZhiqi Mao (1)*, Xin Wang (2)*, Xin Xu (1), Zhiqiang Cui (1), Longsheng Pan (1), Xiaojing Ning (3), Baixuan Xu (3), Lin Ma (4), Zhipei Ling (1), Jianjun Jia (5), Xinguang Yu (1,2)(1) Department of Neurosurgery, Chinese PLA General Hospital, Beijing, China, (2) School of Medicine, Nankai Univer-sity, Tianjin, China, (3) Department of Nuclear Medicine, Chinese PLA General Hospital, Beijing, China, (4) Department of Radiology, Chinese PLA General Hospital, Beijing, China, (5) Department of Neurology, Chinese PLA General Hospi-tal, Beijing, China

OC12 : 严重阿尔茨海默氏病患者应用脑深部电刺激穹隆初期的部分功能改善毛之奇(1)*, Xin Wang(2)*, 徐欣(1), 崔志强(1), 潘隆盛(1), Xiaojing Ning(3), 徐白萱(3), 马林(4), 凌至培(1), 贾建军(5), 余新光(1,2)(1) 解放军总医院神经外科, 中国北京 (2) 南开大学医学院，中国天津。(3) 解放军总医院核医学科，中国北京 (4) 解放军总医院放射学科，中国北京 (5) 解放军总医院神经内科，中国北京

3:00 - 3:15 pm OC13: YXQN Medicine Ameliorates Alzheimer’s Disease- Cognitive Impairment and Pathology in Transgenic MiceXiao-meng Li MD, Ph D (1), Xiao-wan Wang MD, Ph D (1), Li-chun Wang Ph D (1), Xu Dong, BS (1), Jia-le Li, BS (1), Si-tong Liu MS (1), Jiang Li*, MD, PhD (2)(1) The Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal Univer-sity, Changchun, China, (2) Dental Hospital, Jilin University, Changchun, China

OC13 : 养血清脑药对阿尔茨海默氏病的改善——转基因小鼠的认知障碍及病理学李晓萌，医学博士与哲学博士(1), Xiao-wan Wang，医学博士与哲学博士(1), Li-chun Wang，哲学博士(1), Xu Dong, 理学学士(1), Jia-le Li, 理学学士(1), Si-tong Liu，理学硕士(1), Jiang Li*, 医学博士与哲学博士(2)。(1) 东北师范大学遗传与细胞研究所分子表观遗传学教育部重点实验室（中国长春）(2) 吉林大学口腔医院（中国长春）

3:15 - 3:30 pm OC14: Elenbecestat (E2609), a BACE inhibitor: Results from a Phase-2 study in subjects with Mild Cognitive Impairment (MCI) and mild-to-moderate dementia due to Alzheimer’s disease (AD)Shau Yu Lynch, PhD, June Kaplow, PhD, Jim Zhao, MS, MM, Shobha Dhadda, PhD, Johan Luthman, PhD, DDS, Bruce Albala, PhDEisai Inc. Woodcliff Lake, NJ, USA

OC14 : Elenbecestat (E2609)——BACE抑制剂：阿尔茨海默氏病（AD）引起的轻度认知障碍（MCI）和轻度至中度痴呆症的受试者二期临床研究结果 Shau Yu Lynch，哲学博士；June Kaplow，哲学博士；Jim Zhao，理学硕士与管理学硕士；Shobha Dhadda，哲学博士；Johan Luthman，哲学博士与牙科博士；Bruce Albala，哲学博士Eisai Inc.（美国新泽西州伍德克利夫湖）

3:30 - 3:45 pmOC15: Development of Novel PET Imaging Tracers for Neurodegenerative DiseasesPaul Tempest (1), Gilles Tamagan (3), Ken Marek3, John Seibyl (3), Vincent Carroll (3), Olivier Barret (3), David Alagille (3), Kun-Ju Lin (4), Ing-Tsung Hsiao (4), Qing-Fang Yang (4), Maiko Ono (2), Hitoshi Shimada (2), Nirahiko Suhara (2), Ming-Rong Zhang (2), Makoto Higuchi (2), Chin Yin Tai (1), Ming-Kuei Jang (1)(1) APRINOIA Therapeutics - Taipei, Taiwan, (2) National Institute for Quantum and Radiological Science and Techno-logy (QST) - Chiba, Japan, (3) Invicro - New Haven, CT USA, (4) Chang Gung Memorial Hospital and Chang Gung Uni-versity - Tao-Yuan, Taiwan

OC15 : 神经退行性疾病的新型PET成像示踪剂的研发Paul Tempest(1)、Gilles Tamagan(3)、 Ken Marek(3)、John Seibyl(3)、Vincent Carroll(3)、Olivier Barret(3)、David Alagille(3)、Kun-Ju Lin(4)、Ing-Tsung Hsiao(4)、Qing-Fang Yang(4)、Maiko Ono(2)、 Hitoshi Shimada(2)、Nirahiko Suhara(2)、Ming-Rong Zhang(2)、Makoto Higuchi(2)、Chin Yin Tai(1)、 Ming-Kuei Jang(1) (1)APRINOIA Therapeutics（台湾台北）(2)国立研究开发法人量子科学技术研究开发机构(QST)（日本千叶县）(3)Invicro（美国康涅狄格州纽黑文）(4)长庚纪念医院和长庚大学（台湾桃园）

3:45 - 4:15 pm Coffee break and poster sessions - 茶歇和海报环节

9月2日星期日会议日程





4:15 - 4:35 pm CONFERENCE 会议Chair: Feng Lei 主席：封磊What can China Aging and Alzheimer’s Disease Initiative, CAADI, help for early diagnosis of Alzheimer’s disease and related clinical trials?Yong Shen, PhDNeurodegenerative Disease Research Center (NDRC) and Brain Bank, University of Science and Technology of ChinaInstitute on Aging and Brain Disorders中国衰老及阿尔茨海默氏病计划（CAADI）能为阿尔茨海默氏病的早期诊断及相关临床试验带来什么样的帮助？申勇, 哲学博士中国科技大学脑资源库暨神经退行性疾病研究中心脑衰老及脑疾病研究中心

4:35 - 5:00 pm Closing Ceremony闭幕式

会议日程



POSTERSP1CHORAL SINGING FOR THE PREVENTION OF DEMENTIA: STUDY DESIGN OF A RANDOMIZED CLINICAL TRIALLei Feng, MD, PhD (1), Rui Wang, PhD (2), Iris Rawtaer, MBBS, MMed (3), F. H. Maurine Tsakok, MBBS, MMed, PhD (4), Bernard Lanskey, BMus, MMus (5), Chay Hoon Tan, MD, PhD (6), Lee-Gan Goh, MBBS, MMed (7), Rathi Mahendran, MBBS, MMed11 (3), Ee-Heok Kua, MBBS, MMed, MD (1,3)(1) Department of Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, (2) Aging Research Center, Karolinska Institutet, Sweden, (3) Department of Psychological Medicine, National University Hospital, Singapore, (4) National University of Singapore Society Choir, Singa-pore, (5) Yong Siew Toh Conservatory of Music, National University of Singapore, (6) Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, (7) Department of Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

用于预防痴呆症的合唱：随机临床试验的研究设计封磊，医学博士与哲学博士 (1), Rui Wang, 哲学博士(2), Iris Rawtaer, 内外全科医学士、医学硕士(3), F. H. Maurine Tsakok, 内外全科医学士、医学硕士、哲学博士(4), Bernard Lanskey, 音乐学士、音乐硕士(5), Chay Hoon Tan, 医学博士与哲学博士(6), Lee-Gan Goh, 内外全科医学士、医学硕士(7), Rathi Mahendran, 内外全科医学士、医学硕士(3), Ee-Heok Kua, 内外全科医学士、医学硕士、医学博士(1,3)(1)新加坡国立大学杨潞龄医学院心理医学系, 新加坡 (2)卡罗林斯卡学院老龄研究中心, 瑞典 (3)国立大学医院心理科, 新加坡 (4)新加坡国立大学合唱社团, 新加坡 (5)新加坡国立大学杨秀桃音乐学院 (6)新加坡国立大学杨潞龄医学院药理学系, 新加坡 (7)新加坡国立大学杨潞龄医学院家庭医学系, 新加坡

P2NUTRITIONAL INTERVENTION IN MILD ALZHEIMER’S DISEASE IN CHINESE: LOCAL EXPERIENCE ON SOUVENAID Leung-Wing Chu, MD, FRCP, FHKCP, FHKAM(Medicine) (1,2) (1) Honorary Clinical Professor, Department of Medicine, The University of Hong Kong, (2) Director, Hong Kong Brain Memory Centre, Hong Kong

中国中度阿尔茨海默氏病的营养干预：Souvenaid的当地经验 Leung-Wing Chu, 医学博士、皇家内科医师学会会员、香港内科医学院院士、香港医学专科学院院士(内科) (1,2) (1)名誉临床教授, 香港大学内科学系；(2)香港脑记忆中心主任，香港

P3COMPARISON OF THE USEFULNESS OF BRAIN PERFUSION SPECT, DAT-SPECT, ANDMIBG SCINTIGRAPHY FOR THE DIAGNOSIS OF DEMENTIA WITH LEWY BODIESSeiju Kobayashi (1,2), Kanae Makino (2), Shigeki Hatakeyama (3), Tomo Iwamoto (2), Kumiko Utsumi (4),Chiaki Kawanishi (2)(1) Shinyukai Nakae Hospital, Sapporo, Japan, (2) Department of Neuropsychiatry, Sapporo Medical University Graduate Schoolof Medicine, Sapporo, Japan, (3) Department of Psychiatry, Kushiro Red Hospital, (4) Department of Psychiatry, Sunagawa City Medical Center, Sunagawa, Japan

SPECT、DAT-SPECT脑血流灌注成像与间碘苄胺（MIBG）闪烁扫描对路易体痴呆症诊断的有用性比较 Seiju Kobayashi (1,2).Kanae Makino (2), Shigeki Hatakeyama (3), Tomo Iwamoto (2), Kumiko Utsumi (4), Chiaki Kawanishi (2)(1)心优会中江医院, 日本札幌。(2)札幌医科大学内科研究生院神经精神病学系，日本札幌。(3)钏路红十字医院精神病科 (4)砂川市立医院精神病科，日本砂川。

P4SERUM PROTEIN-BASED PROFILES AS NOVEL BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASEYue-Ping Liu (1), a, Shu Yu (1,2), a(1) Department of Laboratory Medicine, 477TH Hospital of PLA, Xiangyang, Hubei Province, China, (2) State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Disease & Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an , Shaanxi Province, China

血清蛋白指纹图谱成为诊断阿尔茨海默氏病的新型生物标记Yue-Ping Liu (1), a, Shu Yu (1,2), a (1) 中国人民解放军477医院检验科，中国湖北省襄阳。(2) 第四军医大学口腔医学院检验系，军事口腔医学国家重点实验室、国家口腔疾病临床医学研究中心、陕西口腔疾病临床医学研究中心，中国陕西省西安

P5EFFECT OF THE BET PROTEIN INHIBITOR APABETALONE ON SERUM MARKERS OF POTENTIAL IMPORTANCE FOR COGNITIVE DECLINE IN CARDIOVASCULAR DISEASE PATIENTSJ. Cummings2, J. Johansson (2), E. Kulikowski (3), N.C. Wong (3), C. Halliday (3), K. Lebioda (3), A. Khan (3), B. Winblad (4), H. Zetterberg (5), M. Sweeney (2) (1) Cleveland Clinic Lou Ruvo, Center for Brain Health, Las Vegas, USA, (2) Resverlogix Corp., Research and Development, San Francisco, USA, (3) Resverlogix Corp., Research and Development, Calgary, Canada, (4) Karolinska Institute, Dept NVS, Div. of Neurogeriatrics, Huddinge, Sweden, (5) Sahlgrenska Academy at the University of Gothenburg, Department of Psychiatry and Neurochemistry- Institute of Neuroscience and Physiology, Gothenburg, Sweden

BET蛋白抑制剂Apabetalone用于治疗心血管疾病患者认知功能衰退时对具有潜在重要性的血清标志物的作用 J. Cummings (2), J. Johansson (2), E. Kulikowski (3), N.C.Wong (3), C. Halliday (3), K. Lebioda (3), A. Khan (3), B. Winblad (4), H. Zetterberg (5), M. Sweeney (2)(1) Cleveland Clinic Lou Ruvo脑健康中心，美国拉斯维加斯 (2) Resverlogix Corp., 研发部, 美国旧金山 (3) Resverlogix Corp., 研发部, 加拿大卡尔加里 (4) 卡罗林斯卡学院，神经病学体征科, 老年神经病学系, 瑞典胡丁厄 (5) 哥德堡大学萨尔格雷斯卡学院, 精神病与神经化学系- 神经科学与心理学学院, 瑞典哥德堡

P6ASSESSMENT INSTRUMENTS USED IN NEW DRUG PHASE III RANDOMIZED CLINICAL TRIALS FOR ALZHEIMER DISEASEHai-Ning He (1), Shi-Fu Xiao, PhD (1), Tao Wang, PhD (1)(1) Department of Geriatric Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University - China



POSTERS阿尔茨海默氏病新药三期随机临床试验所使用的评估工具Hai-Ning He (1), Shi-Fu Xiao, 哲学博士 (1), Tao Wang, 哲学博士 (1)(1)上海交通大学医学院附属上海市精神卫生中心老年精神病科；上海交通大学阿尔茨海默氏病诊治中心——中国

P7MITOPHAGY IS ASSOCIATED WITH EXERCISE-INDUCED IMPROVEMENT OF MITOCHONDRIAL DYSFUNCTION IN APP/PS1 TRANSGENIC MICENa Zhao, MD (1,2), Qing-Wei Yan, PhD (1,3), Ling-Yu Yin, MD (1,2), Bo Xu, PhD* (1,2)(1) Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, East China Normal University, Shanghai, China, (2) School of Physical Education & Health Care, East China Normal University, Shanghai, China, (3) School of Physical Education, Xi zang Minzu University, Xia-nyang, China

线粒体自噬与运动诱发的APP/PS1转基因小鼠线粒体功能障碍改善相关Na Zhao, 医学博士 (1,2), Qing-Wei Yan, 哲学博士 (1,3), Ling-Yu Yin, 医学博士 (1,2), Bo Xu, 哲学博士*(1,2)(1) 华东师范大学“青少年健康评价与运动干预”教育部重点实验室，中国上海 (2) 华东师范大学体育与健康学院, 中国上海 (3) 西藏民族大学体育学院，中国咸阳

P8EXERCISE IMPROVES HIPPOCAMPAL MITOCHONDRIAL MORPHOLOGY IN APP/PS1 TRANSGENIC MICEBaixia Li, PhD (1,2), Xiaoyan Ding, MD (1,2), Fei Liang,PhD (1,2),Chenfei Zhang, MD (1,2),Bo Xu, PhD* (1,2)(1) Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, East China Normal University, Shanghai, China, (2) School of Physical Education & Health Care, East China Normal University, Shanghai, China

运动改善APP/PS1转基因小鼠海马线粒体形态Baixia Li, 哲学博士 (1,2), Xiaoyan Ding, 医学博士 (1,2), Fei Liang,哲学博士 (1,2), Chenfei Zhang, 医学博士 (1,2), Bo Xu, 哲学博士*(1,2)(1) 华东师范大学“青少年健康评价与运动干预”教育部重点实验室，中国上海 (2) 华东师范大学体育与健康学院, 中国上海

P9THE EFFECT OF TREADMILL EXERCISE ON AB EFFLUX CLEARANCE IN HIPPOCAMPUS OF TG APP/PS1 MICE HE Biao (1), XU Bo (2) (1) P.E.Dept. Anhui Normal University, Wu hu, (2) Key Laboratory of Adolescent Health Assessment and Exercise Intervention of Ministry of Education, East China Normal University, Shanghai China

跑步机锻炼对APP/PS1转基因小鼠海马体β-淀粉样蛋白流出物清除率的影响 HE Biao (1), XU Bo (2) (1) 安徽师范大学体育系，芜湖 (2) 华东师范大学“青少年健康评价与运动干预”教育部重点实验室，中国上海

P10ADUCANUMAB: 24-MONTH ANALYSIS FROM PRIME, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 1B STUDY IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER’S DISEASEPhilipp von Rosenstiel MD (1), Sarah Gheuens, MD, PhD (1), Tianle Chen, PhD (1), John O’Gorman, PhD (1), Ping Chiao, PhD (1), Guanfang Wang, PhD (2), Christian von Hehn, MD, PhD (1), LeAnne Skordos PharmD (1), Christoph Hock, MD (3), Roger M Nitsch, MD (3), Samantha Budd Haeberlein, PhD (1), Alfred Sandrock, MD, PhD (1)(1) Biogen, Cambridge, MA – USA, (2) Cytel, Cambridge, MA – USA, (3) Neurimmune, Schlieren-Zurich, and University of Zurich – Switzerland

Aducanumab: 对前驱或轻度阿尔茨海默氏病患者进行随机双盲安慰剂对照1b期（PRIME）研究的24个月分析Philipp von Rosenstiel 医学博士 (1), Sarah Gheuens, 医学博士与哲学博士 (1), Tianle Chen, 哲学博士 (1), John O’Gorman, 哲学博士 (1), Ping Chiao, 哲学博士 (1), Guanfang Wang, 哲学博士 (2), Christian von Hehn, 医学博士与哲学博士 (1), LeAnne Skordos 药学博士 (1), Christoph Hock, 医学博士 (3), Roger M Nitsch, 医学博士 (3), Samantha Budd Haeberlein, 哲学博士 (1), Alfred Sandrock, 医学博士与哲学博士 (1)(1) Biogen, 美国马萨诸塞州剑桥 (2) Cytel, 美国马萨诸塞州剑桥 (3) Neurimmune, 苏黎世施利伦与苏黎世大学 – 瑞士

P11PIAS1 SER-503 PHOSPHORYLATION-MEDIATED ELK-1 SUMOYLATION PROMOTES NEURONAL SURVIVAL IN APP/PS1 MICEEminy H.Y. Lee, PhD (1), Shau-Yu Liu, PhD (1), Yun-Li Ma, MS (1), Wei-Lun Hsu, PhD (1), Hsin-Ying Chiou, PhD (1,2)(1) Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, (2) Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

PIAS1 Ser-503磷酸化介导的Elk-1 SUMO化提高APP / PS1小鼠的神经元存活率Eminy H.Y. Lee，哲学博士(1), Shau-Yu Liu，哲学博士(1), Yun-Li Ma，理学硕士(1), Wei-Lun Hsu，哲学博士(1), Hsin-Ying Chiou，哲学博士(1,2) (1) 中央研究院生物医学科学研究所（台湾台北）, (2) 高雄医学大学附设中和纪念医院内科部内分泌代谢科（台湾高雄）


Congress venue - 会场地点

HILTON HONGQIAO SHANGHAI 1116 Hongsong E Rd, Minhang Qu,

Shanghai Shi, China, 201103

上海虹桥元一希尔顿酒店上海市闵行区红松东路1116号，邮编：201103

CTAD Asia-China has negotiated special prices to stay at the conference hotel at the price of CNY1050 net per night with breakfast. You can now book your hotel room here.

CTAD亚洲-中国与会议酒店达成特价协议，以每晚1050元的净价入住（含早餐）

您现在可以在这里预订酒店房间。

SILVER SPONSORS - 银牌赞助商

We would like to thank our Silver Sponsors for their support

感谢我们银牌赞助商的支持



We would like to thank our Gold Sponsors for their support

感谢我们金牌赞助商的支持

GOLD SPONSORS - 金牌赞助商

PLEASE CONTACT USFOR MORE INFORMATION

CTAD CONGRESS154, Avenue de Lodève34070 Montpellier, France

[email protected]+33 4 67 10 92 23WWW.CTAD-ASIA.COM

请联系我们了解更多信息

大会秘书处154, Avenue de Lodève

34070 Montpellier, France

[email protected]+33 4 67 10 92 23WWW.CTAD-ASIA.COM

See you next year and keep in touch明年见，保持联系

ASIA-CHINA ·...

Documents

Transcript of ASIA-CHINA ·...